vs
Side-by-side financial comparison of CIVITAS RESOURCES, INC. (CIVI) and Zoetis (ZTS). Click either name above to swap in a different company.
Zoetis is the larger business by last-quarter revenue ($2.3B vs $1.2B, roughly 1.9× CIVITAS RESOURCES, INC.). On growth, Zoetis posted the faster year-over-year revenue change (2.9% vs -8.2%). Over the past eight quarters, CIVITAS RESOURCES, INC.'s revenue compounded faster (1.8% CAGR vs -2.1%).
Civitas Resources, Inc. is a U.S.-based sustainable energy enterprise focused on the exploration, development, and production of oil, natural gas, and natural gas liquids. It primarily operates across the Denver-Julesburg Basin in Colorado, prioritizing low-emission, responsible energy production to meet diverse North American energy demand.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
CIVI vs ZTS — Head-to-Head
Income Statement — Q3 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.2B | $2.3B |
| Net Profit | — | $601.0M |
| Gross Margin | — | 71.7% |
| Operating Margin | 20.0% | — |
| Net Margin | — | 26.6% |
| Revenue YoY | -8.2% | 2.9% |
| Net Profit YoY | — | -0.2% |
| EPS (diluted) | $1.99 | $1.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $2.3B | ||
| Q4 25 | — | $2.4B | ||
| Q3 25 | $1.2B | $2.4B | ||
| Q2 25 | $1.1B | $2.5B | ||
| Q1 25 | $1.2B | $2.2B | ||
| Q4 24 | $1.3B | $2.3B | ||
| Q3 24 | $1.3B | $2.4B | ||
| Q2 24 | $1.3B | $2.4B |
| Q1 26 | — | $601.0M | ||
| Q4 25 | — | $603.0M | ||
| Q3 25 | — | $721.0M | ||
| Q2 25 | — | $718.0M | ||
| Q1 25 | — | $631.0M | ||
| Q4 24 | — | $581.0M | ||
| Q3 24 | — | $682.0M | ||
| Q2 24 | — | $624.0M |
| Q1 26 | — | 71.7% | ||
| Q4 25 | — | 70.2% | ||
| Q3 25 | — | 71.5% | ||
| Q2 25 | — | 73.6% | ||
| Q1 25 | — | 72.0% | ||
| Q4 24 | — | 69.5% | ||
| Q3 24 | — | 70.6% | ||
| Q2 24 | — | 71.7% |
| Q1 26 | — | — | ||
| Q4 25 | — | 31.9% | ||
| Q3 25 | 20.0% | 37.0% | ||
| Q2 25 | 15.3% | 36.7% | ||
| Q1 25 | 20.7% | 36.5% | ||
| Q4 24 | 15.4% | 31.6% | ||
| Q3 24 | 30.6% | 36.6% | ||
| Q2 24 | 21.6% | 33.0% |
| Q1 26 | — | 26.6% | ||
| Q4 25 | — | 25.3% | ||
| Q3 25 | — | 30.0% | ||
| Q2 25 | — | 29.2% | ||
| Q1 25 | — | 28.4% | ||
| Q4 24 | — | 25.1% | ||
| Q3 24 | — | 28.6% | ||
| Q2 24 | — | 26.4% |
| Q1 26 | — | $1.42 | ||
| Q4 25 | — | $1.37 | ||
| Q3 25 | $1.99 | $1.63 | ||
| Q2 25 | $1.34 | $1.61 | ||
| Q1 25 | $1.99 | $1.41 | ||
| Q4 24 | $1.56 | $1.29 | ||
| Q3 24 | $3.01 | $1.50 | ||
| Q2 24 | $2.15 | $1.37 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $56.0M | — |
| Total DebtLower is stronger | $5.1B | — |
| Stockholders' EquityBook value | $6.7B | — |
| Total Assets | $15.1B | — |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $56.0M | $2.1B | ||
| Q2 25 | $69.0M | $1.4B | ||
| Q1 25 | $20.0M | $1.7B | ||
| Q4 24 | $76.0M | $2.0B | ||
| Q3 24 | $47.1M | $1.7B | ||
| Q2 24 | $91.9M | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $5.1B | — | ||
| Q2 25 | $5.4B | — | ||
| Q1 25 | $5.1B | — | ||
| Q4 24 | $4.5B | — | ||
| Q3 24 | $4.8B | — | ||
| Q2 24 | $4.9B | — |
| Q1 26 | — | — | ||
| Q4 25 | — | $3.3B | ||
| Q3 25 | $6.7B | $5.4B | ||
| Q2 25 | $6.8B | $5.0B | ||
| Q1 25 | $6.7B | $4.7B | ||
| Q4 24 | $6.6B | $4.8B | ||
| Q3 24 | $6.7B | $5.2B | ||
| Q2 24 | $6.6B | $5.0B |
| Q1 26 | — | — | ||
| Q4 25 | — | $15.5B | ||
| Q3 25 | $15.1B | $15.2B | ||
| Q2 25 | $15.4B | $14.5B | ||
| Q1 25 | $15.3B | $14.1B | ||
| Q4 24 | $14.9B | $14.2B | ||
| Q3 24 | $15.0B | $14.4B | ||
| Q2 24 | $15.0B | $14.2B |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.77× | — | ||
| Q2 25 | 0.79× | — | ||
| Q1 25 | 0.76× | — | ||
| Q4 24 | 0.68× | — | ||
| Q3 24 | 0.73× | — | ||
| Q2 24 | 0.74× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $860.0M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $893.0M | ||
| Q3 25 | $860.0M | $938.0M | ||
| Q2 25 | $298.0M | $486.0M | ||
| Q1 25 | $719.0M | $587.0M | ||
| Q4 24 | $858.2M | $905.0M | ||
| Q3 24 | $835.0M | $951.0M | ||
| Q2 24 | $359.0M | $502.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | $732.0M | ||
| Q3 25 | — | $805.0M | ||
| Q2 25 | — | $308.0M | ||
| Q1 25 | — | $438.0M | ||
| Q4 24 | — | $689.0M | ||
| Q3 24 | — | $784.0M | ||
| Q2 24 | — | $370.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | 30.7% | ||
| Q3 25 | — | 33.5% | ||
| Q2 25 | — | 12.5% | ||
| Q1 25 | — | 19.7% | ||
| Q4 24 | — | 29.7% | ||
| Q3 24 | — | 32.8% | ||
| Q2 24 | — | 15.7% |
| Q1 26 | — | — | ||
| Q4 25 | — | 6.7% | ||
| Q3 25 | — | 5.5% | ||
| Q2 25 | — | 7.2% | ||
| Q1 25 | — | 6.7% | ||
| Q4 24 | — | 9.3% | ||
| Q3 24 | — | 7.0% | ||
| Q2 24 | — | 5.6% |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.48× | ||
| Q3 25 | — | 1.30× | ||
| Q2 25 | — | 0.68× | ||
| Q1 25 | — | 0.93× | ||
| Q4 24 | — | 1.56× | ||
| Q3 24 | — | 1.39× | ||
| Q2 24 | — | 0.80× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CIVI
| Crude Oil Natural Gas And Natural Gas Liquids | $1.2B | 99% |
| Oil And Gas Operation And Maintenance | $8.0M | 1% |
| Natural Gas Reserves | $2.0M | 0% |
ZTS
| Companion Animal | $1.5B | 67% |
| Livestock | $720.0M | 32% |
| Contract Manufacturing & Human Health | $23.0M | 1% |
